Allist(SH:688578) Zheng Quan Zhi Xing·2025-09-01 16:27Core Viewpoint - Shanghai Ailis Pharmaceutical Technology Co., Ltd. announced a change in shareholder equity that has crossed the 1% threshold due to a reduction in shareholding by major shareholders [1][2]. Group 1: Shareholder Equity Changes - Shareholders Shanghai Aixiang Enterprise Development Center (Limited Partnership) and Nantong Aiyun Enterprise Development Center (Limited Partnership) reduced their combined shareholding from 53.05% to 51.87% after selling 5,316,500 shares on September 1, 2025 [2]. - The specific share reduction included 4,231,726 shares sold by Shanghai Aixiang and 1,084,774 shares sold by Nantong Aiyun [2]. Group 2: Shareholding Structure - After the reduction, the shareholding structure is as follows: - Shanghai Aixiang: 23,340,850 shares (51.87%) - Nantong Aiyun: 8,685,588 shares (1.93%) [2]. - The remaining shareholders, including Du Jinhao, Shanghai Qiaoke Enterprise Development Co., Ltd., Jeffrey Yang Guo, and Jennifer Guo, did not change their holdings [2]. Group 3: Compliance and Future Plans - The company confirmed that the reduction does not trigger mandatory tender offer obligations and will not affect the control or governance structure of the company [2]. - The shareholders have committed to continue adhering to relevant laws and regulations and will fulfill subsequent information disclosure obligations [2].